AstraZeneca Moves To Fend Off Generic Seroquel

Law360, New York (February 8, 2008, 12:00 AM EST) -- In an attempt to stave off the launch of a generic copy of its top-selling anti-psychotic drug Seroquel, AstraZeneca Pharmaceuticals LP has asked a federal court for permission to file a summary judgment motion in its spat with generics drugmaker Teva Pharmaceutical USA Inc.

In a letter filed Wednesday with U.S. District Court for the District of New Jersey, lawyers for AstraZeneca said the proposed motion was necessary given the “imminent expiration” of the 30-month regulatory freeze on the launch of Teva's version of the pill....
To view the full article, register now.